for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Regeneron Pharmaceuticals Inc

REGN.O

Latest Trade

640.34USD

Change

-0.54(-0.08%)

Volume

660,087

Today's Range

632.42

 - 

650.49

52 Week Range

271.37

 - 

653.53

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
640.88
Open
650.41
Volume
660,087
3M AVG Volume
28.64
Today's High
650.49
Today's Low
632.42
52 Week High
653.53
52 Week Low
271.37
Shares Out (MIL)
112.52
Market Cap (MIL)
63,729.14
Forward P/E
23.78
Dividend (Yield %)
--

Next Event

Q2 2020 Regeneron Pharmaceuticals Inc Earnings Release

Latest Developments

More

HHS, DoD Partner With Regeneron On Large-Scale Manufacturing Of COVID-19 Investigational Therapy

Regeneron Announces Manufacturing And Supply Agreement For BARDA And U.S. Department Of Defense For REGN-COV2 Anti-Viral Antibody Cocktail

Regeneron Announces Start Of Regn-Cov2 Phase 3 Covid-19 Prevention Trial With National Institute Of Allergy And Infectious Diseases

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Industry

Biotechnology & Drugs

Contact Info

777 Old Saw Mill River Rd

TARRYTOWN, NY

10591-6717

United States

+1.914.8477000

https://www.regeneron.com/

Executive Leadership

P. Roy Vagelos

Chairman of the Board, Director

Leonard S. Schleifer

President, Chief Executive Officer, Director

George D. Yancopoulos

President, Chief Scientific Officer, Director

Robert E. Landry

Chief Financial Officer, Executive Vice President - Finance

Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

Key Stats

2.15 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

5.9K

2018

6.7K

2019

7.9K

2020(E)

7.6K
EPS (USD)

2017

16.320

2018

22.840

2019

24.670

2020(E)

26.919
Price To Earnings (TTM)
31.51
Price To Sales (TTM)
7.99
Price To Book (MRQ)
5.80
Price To Cash Flow (TTM)
25.55
Total Debt To Equity (MRQ)
5.89
LT Debt To Equity (MRQ)
5.89
Return on Investment (TTM)
18.20
Return on Equity (TTM)
15.93

Latest News

Latest News

U.S. signs $450 million contract with Regeneron for COVID-19 therapy

The U.S. government signed a $450 million contract with Regeneron Pharmaceuticals Inc <REGN.O> for its potential COVID-19 antibody cocktail, the drugmaker said on Tuesday.

BRIEF-Regeneron Announces Manufacturing And Supply Agreement For BARDA And U.S. Department Of Defense For REGN-COV2 Anti-Viral Antibody Cocktail

* REGENERON ANNOUNCES MANUFACTURING AND SUPPLY AGREEMENT FOR BARDA AND U.S. DEPARTMENT OF DEFENSE FOR REGN-COV2 ANTI-VIRAL ANTIBODY COCKTAIL

Regeneron signs $450 mln contract with U.S. govt for COVID-19 therapy

Regeneron Pharmaceuticals Inc said on Tuesday the U.S. government has granted the drugmaker a $450 million contract to make and supply its double antibody cocktail that is being tested against COVID-19.

Regeneron starts COVID-19 antibody cocktail late-stage trials, shares rise

Regeneron Pharmaceuticals Inc <REGN.O> said on Monday it has started late-stage clinical trials to assess the effectiveness of its antibody cocktail in preventing and treating COVID-19.

Regeneron begins COVID-19 antibody cocktail late-stage trial

Regeneron Pharmaceuticals Inc said on Monday it began late-stage clinical trials to assess the effectiveness of its antibody cocktail in preventing and treating COVID-19.

BRIEF-Regeneron Announces Start Of Regn-Cov2 Phase 3 Covid-19 Prevention Trial With National Institute Of Allergy And Infectious Diseases

* REGENERON ANNOUNCES START OF REGN-COV2 PHASE 3 COVID-19 PREVENTION TRIAL IN COLLABORATION WITH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID)

Regeneron, Sanofi arthritis drug fails COVID-19 study

Regeneron Pharmaceuticals Inc and Sanofi said on Thursday their rheumatoid arthritis drug Kevzara failed to meet the main goals of a U.S. study testing it in the most critically ill COVID-19 patients.

Regeneron, Sanofi arthritis drug fails late-stage study in COVID-19 patients

Regeneron Pharmaceuticals Inc and Sanofi said on Thursday their rheumatoid arthritis drug Kevzara failed to meet the main goals of a late-stage study testing it in COVID-19 patients.

BRIEF-Regeneron Says Co And Sanofi Provide Update On Kevzara Phase 3 U.S. Trial In COVID-19 Patients

* REGENERON AND SANOFI PROVIDE UPDATE ON KEVZARA® (SARILUMAB) PHASE 3 U.S. TRIAL IN COVID-19 PATIENTS

BRIEF-Regeneron Pharmaceuticals Inc Says "There Is No Merit To Civil Complaint Filed By U.S. Attorney For District Of Massachusetts"

* REGENERON PHARMACEUTICALS INC SAYS "THERE IS NO MERIT TO CIVIL COMPLAINT FILED BY U.S. ATTORNEY FOR DISTRICT OF MASSACHUSETTS"

U.S. claims Regeneron paid kickbacks via charity to boost expensive drug

The U.S. Justice Department on Wednesday sued Regeneron Pharmaceuticals Inc, accusing it of using a charity that helps cover Medicare patients' drug costs as a means to pay kickbacks for using its expensive macular degeneration drug Eylea.

U.S. alleges Regeneron used drug charity to pay kickbacks

The U.S. Justice Department on Wednesday sued Regeneron Pharmaceuticals Inc, accusing it of using a charity that helps cover Medicare patients' drug costs as a means to pay kickbacks for using its expensive macular degeneration drug Eylea.

BRIEF-Kymab Wins Supreme Court Case Against Regeneron

* KYMAB WINS SUPREME COURT CASE AGAINST REGENERON Source text for Eikon: Further company coverage:

BRIEF-Regeneron's Dupixent Included In List Of Overseas Approved Drugs That Meet Urgent Clinical in China

* DUPIXENT® (DUPILUMAB) APPROVED IN CHINA FOR ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Regeneron begins human testing of COVID-19 antibody cocktail

Regeneron Pharmaceuticals Inc on Thursday said it has begun human testing of its experimental antibody cocktail as a treatment for COVID-19, the disease caused by the novel coronavirus.

Regeneron begins human testing of COVID-19 antibody cocktail

Regeneron Pharmaceuticals Inc on Thursday said it has begun human testing of its experimental antibody cocktail as a treatment for COVID-19, the disease caused by the novel coronavirus.

Healthcare group Sanofi upbeat on Dupixent opportunities

French healthcare company Sanofi outlined more growth opportunities on Thursday for the Dupixent product it is developing along with partner Regeneron .

BRIEF-Regeneron Announces Virtual-Only Format For 2020 Annual Meeting Of Shareholders

* REGENERON ANNOUNCES VIRTUAL-ONLY FORMAT FOR 2020 ANNUAL MEETING OF SHAREHOLDERS Source text for Eikon: Further company coverage:

BRIEF-Regeneron, Intellia Expand Collaboration To Develop Crispr/Cas9-Based Treatments

* REGENERON AND INTELLIA THERAPEUTICS EXPAND COLLABORATION TO DEVELOP CRISPR/CAS9-BASED TREATMENTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up